

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Novel approaches for the design and discovery of quorum-sensing inhibitors.

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/143270> since 2020-11-03T10:22:45Z

Published version:

DOI:10.1517/17460441.2014.894974

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

*[Expert Opin Drug Discov, 9(4) , 2014, DOI 10.1517/17460441.2014.894974]
ovvero [Scutera S, Zucca M, Savoia D, 9, Informa Healthcare,2014, pagg. 353-66]*

The definitive version is available at:

La versione definitiva è disponibile alla URL:

[<http://informahealthcare.com/doi/abs/10.1517/17460441.2014.894974>]

1 ***Novel approaches for the design and discovery of quorum-sensing inhibitors***

2

3 Sara Scutera, Mario Zucca & Dianella Savoia†

4

5 †University of Torino, S. Luigi Gonzaga Hospital, Department of Clinical and Biological Sciences,
6 Orbassano (To), Italy

7 Abstract

8 **Introduction:** The spread of antibiotic resistance, together with the lack of antibiotics based on
9 novel molecular scaffolds, mark the so-called "post-antibiotic era." Among the potential strategies
10 to develop new anti-infective drugs, interference with bacterial virulence is an attractive approach.

11 The discovery that virulence gene expression is mostly regulated by quorum sensing (QS) raised a
12 lot of interest and prompted a lot of research aimed at finding inhibitors of this mechanism.

13 **Areas covered:** This paper deals with the most recent strategies aimed at discovering new inhibitors
14 able to disrupt the different steps of the QS system, targeting signal production, signal molecules
15 and signal receptors. We provide an overview of the literature including research papers, mostly
16 dealing with inhibitors of the *S. aureus* and *P. aeruginosa* QS systems, and a number of
17 comprehensive reviews dealing with the application of the newest technologies to the field.

18 Prospects and emerging concerns regarding the possible clinical applications are also discussed.

19 **Expert opinion:** QS inhibition is a promising strategy against infections. However, despite the
20 discovery of a huge number of QS inhibitors, with about 40 patents, the potential of QS inhibition is
21 still to be fully assessed. The current validation methods of QS inhibitors must be optimized, and
22 the discovery that QS disruption may favour or select more virulent strains must be investigated in
23 depth. Given the current market-dependent situation, the possibility to develop hits into licensed
24 drugs is likely to be made possible by joint ventures between private companies, academia and
25 public institutions.

26

27 **Keywords:** Antibodies; autoinducers; *P. aeruginosa*; quorum sensing; receptors; *S. aureus*,
28 virulence factors.

29

1 **1. Introduction**

2 Intercellular communication by means of secreted hormone-like molecules (pheromones) is an
3 important natural feature, which in different bacterial species is involved in bioluminescence,
4 virulence, biofilm formation, antibiotic production, competence, conjugation, swarming, motility,
5 and sporulation [1]. For most pathogenic bacteria, the ability to implement this kind of multicellular
6 coordination is critical for disease pathogenesis and host colonization. Quorum sensing (QS) is the
7 term used to describe a density-dependent intercellular communication that allows a coordinated
8 multicellular behaviour in prokaryotes, based on the constitutive production and secretion of small
9 molecules defined quorum sensors or autoinducers (AI) [2]. When the AI concentration reaches a
10 critical detection threshold that depends upon bacterial population density (quorum), the AI
11 interaction with species-specific receptors triggers a signal transduction cascade leading to an
12 alteration in gene expression. The production of a number of virulence factors involved in bacterial
13 pathogenesis and in the formation of bacterial sessile communities called biofilms is based on this
14 mechanism. Biofilms account for more than 80% of human infections [3] and their treatment is
15 highly problematic, because sessile bacteria are up to 1000 times more resistant to antibiotics in
16 comparison to their planktonic counterparts, and are less exposed to the host immune system [4].

17 Since the pioneering work on AI by Tomasz and Hotchkiss [5] and Nealson and co-workers,
18 [6], several AI molecules have been identified, which may be classified as follows: i) AI-1, or N-
19 acyl homoserine lactones (AHLs), which are produced by over 70 species of Gram-negative
20 bacteria; ii) oligopeptides, consisting of 5-17 amino acids, which are generally produced by Gram-
21 positive bacteria; iii) AI-2, a class of furanone-based AI derived from 4,5-dihydroxy-2,3-
22 pentanedione (DPD), which can be produced by both Gram-positive and Gram-negative bacteria
23 and may be considered universal interspecies signalling molecules; and iv) other small molecules
24 that include the *Pseudomonas* quinolone signal (PQS), the *Vibrio cholerae* autoinducer (S)-3-
25 hydroxytridecan-4-one, 3-hydroxypalmitic acid methyl ester, the AI-3 (a small AI with unknown

1 structure, used by enterohemorrhagic *E. coli*), bradyoxetin, and other molecules that do not fall
2 within one of the major groups [7].

3 QS inhibition, also called quorum quenching (QQ), is considered an attractive modality of
4 therapeutic intervention for a series of reasons: i) it would overcome the conventional mechanisms
5 of resistance to antibiotics; ii) a single inhibitor could have multiple effects, being able to interfere
6 with the production of a number of virulence factors and with biofilm formation; iii) in principle,
7 anti-virulence factors should not exert an evolutionary pressure on the targeted bacterial population,
8 avoiding the emergence of resistant strains; iv) avoiding or limiting biofilm formation, QS
9 inhibitors could enhance the efficacy of existing antibiotics; v) except AI-2 members, most AI are
10 species-specific. Consequently, the narrow spectrum of activity of inhibitors should avoid the
11 disruption of beneficial microbiota [8]. It is well known that both prokaryotic and eukaryotic
12 organisms have evolved molecular mechanisms able to carry on QQ activity. The study of the
13 signal degradation systems enacted by different bacteria, plants, and mammals may lead to the
14 design of novel approaches for quenching bacterial QS [9]. Ideally, a QS inhibitor should meet the
15 following criteria: it should be a small molecule, highly specific, non toxic for eukaryotic cells, and
16 chemically stable [10].

17 QQ compounds could be used in many fields, such as human and veterinary medicine,
18 agriculture, and aquaculture. The therapy of chronic infections, which are often due to multiresistant
19 bacterial strains, could benefit particularly from the use of antivirulence drugs [11]. By means of *in*
20 *vitro* and *in vivo* experiments, it has been shown that *P. aeruginosa* QS blockage restores the
21 immune response efficiency favouring the clearance of bacterial biofilms [12].

22 QS systems generally offer three points of attack: the signal generation process, the signal
23 molecule, and the signal receptor [13]. During the last three decades, many natural and synthetic
24 agents belonging to the categories of small non-peptide molecules, peptides, and enzymes, have
25 been identified as QS inhibitors [14]. A very comprehensive review on QS inhibitors has recently
26 been published by Kalia [10]. The field is rapidly evolving, and many inhibitors are being

1 discovered. However, clinical applications are still lacking. To the best of our knowledge, only two
2 clinical trials on QS inhibitors have been performed. In the first one (ClinicalTrials.gov Identifier:
3 NCT00610623), the effect of azithromycin, used as a QS blocker at subinhibitory doses for the
4 prevention of *P. aeruginosa* ventilator-associated pneumonia was evaluated. The authors of the
5 study concluded that the major effect of QS inhibition was the selection of more virulent strains.
6 The second trial (ClinicalTrials.gov Identifier: NCT01201577), completed but with no study results
7 posted, was aimed at studying the effect of orally administered combinations of prebiotics,
8 probiotics and antibiotics on QS signalling molecules and on innate and adaptive immunity in
9 humans.

10 In this article, we focus on modern approaches for the development and validation of QS
11 inhibitors, providing the reader with a comprehensive overview of the recent literature on the
12 subject.

14 **2. Strategies targeting QS signal production**

15 The studies aimed to hit at targeting this step are relatively few, and the field is open for further
16 investigation. Compounds affecting the AHL biosynthesis or efflux pumps are likely to behave as
17 QQ. Substrate analogues of AI, like butyryl-S-adenosylmethionine, holo-acyl carrier protein,
18 sinefungin and L/D-S-adenosylhomocysteine can block AHL production *in vitro*. However, *in vivo*
19 experiments have not been performed, because these homologues are likely to affect the central
20 pathways of amino acid and fatty acid metabolism [15]. Small-molecule inhibitors of the AHL
21 synthase have been identified by Chung et al. [16]. The involvement of multidrug efflux pumps in
22 the QS of *Burkholderia pseudomallei* has been established, suggesting that this pathway could also
23 be exploited [17].

24 Methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) is the product of the
25 *pfs* gene, which is highly conserved across bacterial species. This enzyme is present in bacteria but
26 not in mammals, in which its activity is performed by two different enzymes: methylthioadenosine

1 phosphorylase and purine nucleotide phosphorylase [18]. Beyond playing a crucial role in
2 maintaining homeostasis, MTAN is directly involved in the biosynthesis of AI-1 and AI-2 [19]. For
3 this reason, QS inhibitors belonging to the class of MTAN transition state analogues could be used
4 to block both AI-1 and AI-2 production in bacteria without interfering with host cell metabolism.
5 This approach has been explored by Gutierrez *et al.* [19], and Longshaw *et al.* [20], who found that
6 both sulphur-containing and sulphur-free MTAN transition state analogues are potent inhibitors of
7 *E. coli* QS. Recently, the Schramm laboratory patented two different types of transition state
8 analogues and a pharmaceutically acceptable carrier for treating bacterial infections [21]. These
9 developments indicate the interest that MTAN has aroused as a possible target for bacterial anti-
10 infective drug design [1].

11 It has been demonstrated that anthranilate (**Figure 1, 1**) is a precursor of the PQS (**Figure 1,**
12 **3**), which is a secondary metabolite maximally produced during the late stationary phase of growth.
13 An anthranilate analogue (methyl anthranilate) (**Figure 1, 2**) inhibits the production of PQS, with a
14 negative effect on the production of elastase by *P. aeruginosa* [22]. These data suggest that
15 pseudomonas PQS targeting may have a therapeutic value, but it must be taken into account that *P.*
16 *aeruginosa* has two other QS systems, based on N-(3-oxododecanoyl)-L-homoserine lactone (3-
17 oxo-C12-HSL) (**Figure 2, 4**) and N-butyryl-L-homoserine lactone (C4-HSL) (**Figure 2, 5**),
18 respectively. In this regard, it has recently been shown that eugenol (**Figure 3, 6**), the major
19 constituent of clove extract, affects *P. aeruginosa* QS decreasing the transcriptional activation of
20 both *las* and *pqs* systems, which together regulate the expression of numerous virulence-related
21 genes [23]. Further studies are needed to assess the relative importance of each system on the
22 virulence of *P. aeruginosa*, and to examine the possibility of simultaneously turning off all three
23 systems.

24

25 **3. Strategies targeting QS signal**

1 Neutralization of QS signals has been extensively investigated [24]. Biological inactivation of AHLs
2 can be achieved by enzymatic degradation or antibody-mediated inactivation of the signal molecule.

3

4 **3.1 Enzymes**

5 QQ enzymes can be grouped in two classes: class I includes the enzymes that break the AHL
6 molecule, i.e. AHL-lactonase, AHL-acylase and paraoxonase, whereas class II includes enzymes
7 that reduce carbonyl to hydroxyl, i.e. oxidoreductases [25].

8 About 20 AHL lactonases have been discovered to date, most of which are supposedly
9 valuable for the biocontrol of plant diseases. Recently, Migiyama et al. reported the effect of the
10 AiiM lactonase on a mouse model of acute pneumonia by *P. aeruginosa* [26]. The study supports
11 the therapeutic potential of AHL lactonases in therapy, demonstrating that AiiM is a potent inhibitor
12 of *P. aeruginosa* QS and reduces bacterial virulence. The use of this molecule could represent a
13 new strategy to cure chronic pulmonary infections by multiresistant strains. However, the
14 problematic issue is the way of administration: in their experiments, the authors used lactonase-
15 overexpressing plasmid vector-transformed *P. aeruginosa* to infect mice. This technique can be a
16 good experimental tool, but, of course, it is not of any use for therapeutic purposes. The authors
17 suggest two possible solutions to this impasse: the genetic modification of probiotics, or the local
18 administration of the purified AiiM protein. In both cases, the authors agree that further studies are
19 needed to evaluate the possibility of developing AiiM lactonase into a drug molecule.

20 One of the best studied acylases is the PvdQ protein, a member of the N-terminal
21 nucleophile hydrolase superfamily. This enzyme is produced by the *P. aeruginosa* PAO1 strain,
22 suggesting that it may participate to the regulation of its own QS-dependent pathogenic potential.
23 PvdQ behaved as a QQ *in vitro* in a number of phenotypic assays in which the *pvdQ* gene was
24 overexpressed in *P. aeruginosa*, and its activity was demonstrated *in vivo* in a *Caenorhabditis*
25 *elegans* model [27]. The development of the molecule has reached the stage of the production of a

1 stable and inhalable powder formulation for the treatment of *P. aeruginosa* pulmonary infection
2 [28].

3 Paraoxonases (PON) are a group of Ca²⁺-dependent esterases with AHL lactonase activity
4 widely conserved in mammals, but not present in chicken and fish [29]. In humans, the family
5 comprises three members, whose genes are located on chromosome 7: PON1 and PON3, mainly
6 expressed in liver and kidney, and PON2, expressed in various tissues but not present in plasma
7 [30]. These enzymes are supposed to play an important role in the defence against the formation of
8 bacterial biofilms. The protective effect of PON1 against *P. aeruginosa* infection has been
9 demonstrated in an experimental model of transgenic *Drosophila melanogaster* expressing human
10 PON1 [31]. Recently, by *in vitro* and *in vivo* experiments Devarajian et al. demonstrated that PON2
11 plays an important role in the mouse innate immune response [32].

12 Oxidoreductases catalyze the functional inactivation of AHLs by oxidating or reducing their
13 acyl side chain. Two oxidoreductases have been isolated from cultivated bacteria, one from *Bacillus*
14 *megaterium* CYP102A1 and the other from *Rhodococcus erythropolis* W2 [33, 34]. Recently, a novel
15 oxidoreductase named BpiB09, able to inactivate the 3-oxo-C12-homoserine lactone, was obtained
16 by screening a soil metagenomic library. The expression of this molecule in *P. aeruginosa* PAO1
17 significantly reduced pyocyanin production, bacterial motility, and biofilm formation. In addition,
18 transformed bacteria resulted non pathogenic in a *C. elegans* model of infection [35]. The possibility
19 to screen metagenomic libraries opens wide horizons for the discovery of new active QQ enzymes.
20 However, their value for clinical purposes needs to be assessed. It can be expected that they will
21 find application in the treatment of skin and airway infections, and in the inhibition of bacterial
22 biofilm formation on catheters and prosthetic devices.

23

24 **3.2 Antibodies**

25 Most AHLs exert potent biochemical effects, such as induction of apoptosis and modulation of NF-
26 κB activity, behaving as small-molecule toxins on mammalian cells. Consequently, specific

1 antibodies can achieve the dual purpose of neutralizing both the QS activity and the toxic effect.
2 The immunological approach includes the induction of antibodies by vaccination, and the
3 administration of preformed mono- or poly-clonal antibodies.

4 Following the first demonstration of the efficacy of vaccination with a homoserinelactone-
5 carrier protein conjugate in a mouse model of *P. aeruginosa* lung infection by Miyairi et al. [36], the
6 possibility to produce protective antibodies has been extensively investigated, especially by the
7 Janda laboratory at The Scripps Research Institute [37-39]. The attractiveness of this approach is based
8 on the high evolutionary conservation of AI, their extracellular distribution, and the established
9 knowledge of antibody pharmacodynamic and kinetic properties. The chemical structure and the
10 low molecular weight make the AI poor antigens, which could be more properly defined haptens [7].
11 The efficacy of the immunopharmacotherapeutic approach to the inhibition of QS has been
12 demonstrated *in vitro* and *in vivo* against *S. aureus* and *P. aeruginosa*. Park et al. reported the
13 production of a monoclonal antibody, AP4-24H11, elicited against the autoinducing peptide AIP-4
14 produced by *S. aureus* RN4850. The antibody was able to inhibit QS *in vitro*, suppressed *S. aureus*
15 pathogenicity in an abscess formation mouse model, provided complete protection against a lethal
16 *S. aureus* challenge [38], and its structure was subsequently further investigated in detail [40].

17 Very recently, Palliyil et al. reported the development of monoclonal antibodies against
18 homoserine lactones produced by *P. aeruginosa*. These antibodies were produced by using a
19 combination of sheep immunisation and phage antibody display library construction/selection, and
20 were characterized by high sensitivity (100-1000 times higher than that of any published antibodies
21 raised to the same target). Their protective effect was assessed in a slow-killing model of *C.*
22 *elegans*, and in a mouse model of *P. aeruginosa* infection [41]. These findings provide a strong
23 foundation for further investigations of the potential of AHL monoclonal antibodies in the
24 immunopharmacotherapy of antibiotic resistant strains of *P. aeruginosa*.

25

1 **4. Strategies targeting autoinducer-receptor interaction and/or receptor-** 2 **mediated signal.**

3 The possibility to inhibit the expression of QS signal receptors by means of antisense RNAs has
4 been demonstrated by Hirakawa et al. [42]. For a comprehensive review on the inhibition of signal
5 detection, the reader is referred to [43]. In the following paragraphs, we will discuss some recent
6 insights on the QS of *S. aureus* and *P. aeruginosa* that may suggest the possibility of interfering
7 with the receptor side of the system.

8 The clarification of the QS system in Gram-positive bacteria allowed the identification of
9 molecules inhibiting different steps of the mechanism. The QS system of *S. aureus*, which is the
10 most studied, consists of the accessory gene regulator (*agr*) locus, which is composed of two
11 transcripts called RNAII and RNAIII, driven by the P2 and P3 promoters, respectively. The RNAIII
12 transcript is the effector of the *agr* response, which up-regulates a number of toxins and multiple
13 exoenzymes (proteases, lipases, and nucleases), and down-regulates the expression of numerous
14 surface protein genes. The RNAII transcript is an operon of four genes, *agrBDCA*. AgrD is the 46
15 aminoacid precursor of the secreted AI, a cyclic thiolactone peptide (AIP) of 7-9 aminoacids, which
16 is processed, cyclized and exported through the transmembrane protein AgrB. The extracellular AI
17 binds to AgrC, the transmembrane receptor, which is a histidine kinase that following the binding
18 phosphorylates the AgrA cytoplasmic response regulator, activating the P2 and P3 promoters. More
19 advanced strategies targeting *S. aureus* virulence gene regulation make use of inhibitors of the
20 sensor kinase AgrC, of the transcriptional activator AgrA, or of the RNAIII [44].

21 Due to allelic variations within the *agr* gene system, *S. aureus* can be subdivided into four
22 *agr* specific groups, *agr* I–IV, each secreting a distinct AIP with different primary amino acid
23 sequence. Most cross-group AIP-AgrC interactions are inhibitory, with AIPs activating their
24 cognate receptors and competitively inhibiting non-cognate receptors. The competitive AIP
25 inhibition constitutes a promising therapeutic approach for attenuating *S. aureus* infections.

1 Recently, it has been demonstrated by *in vitro* experiments that oxidized low-density lipoproteins
2 bind all four *S. aureus* agr AIPs and antagonize agr signalling by each agr allele [45].

3 Molecules interfering with the *S. aureus* agr system have been obtained by a marine
4 *Photobacterium*. Due to the structural similarity of these molecules, called solonamides, to the agr
5 AI, the proposed mechanism of action is competitive inhibition [46]. The solonamides are the first
6 reported natural antagonists with a structure resembling that of native *S. aureus* AI. Another natural
7 product, hamamelitannin, obtained from *Hamamelis virginiana* (witch hazel), was identified as an
8 inhibitor of RNAIII and δ -hemolysin production in *S. aureus* by Kiran et al [47].

9 Two of the three *P. aeruginosa* QS systems consist of the *lasRI* and *rhlRI* genes, where
10 LasR and RhlR belong to the LuxR family of transcriptional regulators that specifically bind to *N*-
11 (3-oxododecanoyl)homoserine lactone (3-oxo-C12-HSL) and *N*-butanoylhomoserine lactone (C4-
12 HSL), respectively [48]. The *las* and *rhl* systems regulate over 10% of the *P. aeruginosa* genome
13 and are hierarchically organized. The 3-oxo-C12-HSL signal is the key factor that exerts
14 transcriptional control over *lasI*, *rhlR*, *rhlI* and the genes of the third system, the PQS system.
15 Despite the positive auto-regulation of *lasI*, levels of 3-oxo-C12-HSL reach a steady level long
16 before cultures reach the stationary phase, due to the intervention of the transcriptional repressor
17 RsaL, whose activity was originally reported in 1999 [49; 50]. It is now known that the QS systems
18 are controlled by a complex regulatory network at both the transcriptional and post-transcriptional
19 level, and RsaL is just one of over 15 QS regulators that have been identified so far [51]. RsaL is a
20 DNA binding protein that competes against LasR, directly repressing both *lasI* and *rsaL*
21 transcription by binding to the bi-directional *rsaL-lasI* promoter. In addition, Rampioni et al.
22 observed that, independently of its effects on the production of QS signal molecules, RsaL directly
23 represses 120 genes, many of which code for virulence and antibiotic resistance, and activates 10
24 genes (undefined) [50].

25 A recently identified novel LasR-specific antiactivator is QslA, which binds to LasR and
26 prevents it from binding to its target promoter [52]. The investigation of bacterial autoregulation of

1 QS may open new horizons for the therapeutic exploitation of QS control. Studying the interaction
2 between QslA and the LasR ligand-binding domain, Fan et al. elucidated the crystal structure of
3 QslA and demonstrated that its mechanism of action consists in the disruption of LasR dimers by
4 occupying the LasR dimerization interface, which is a previously unknown mechanism of QS
5 inactivation [53].

6 Other QS negative regulators produced by *P. aeruginosa* are QscR, which is an “orphan”
7 receptor activated by the 3-oxo-C12-HSL signal [54], and QteE, which reduces LasR protein
8 stability without affecting LasR transcription or translation [55]. It has been shown that negative
9 regulation of QS by QteE and QscR has a major impact on the absolute and relative fitness of *P.*
10 *aeruginosa* [56]. The possibility to interact with these regulator systems for therapeutic purposes is
11 currently being investigated. In a recent paper, Weng et al. report on a novel QS inhibitor, called
12 C2, which causes a 375.4% upregulation of the *qscR* gene, resulting in the attenuation of elastase
13 and protease activity, swarming motility and biofilm formation in the *P. aeruginosa* strain
14 PAO1[57].

15 The *P. aeruginosa* PQS system may be inhibited by anthranilic acid halogenated analogues,
16 whose development, however, has not been pursued [58; 59]. However, novel insights on the
17 structure of PqsE, a product of the *pqs* operon, could lay the foundations for the computer-aided
18 design of PqsE inhibitors [60]. Antagonists of the PqsR were reported for the first time in 2012 [61],
19 and a peculiar mechanism of functional inversion of a PqsR antagonist has been recently described
20 by Lu et al. [59]. These authors observed that compound 1 (**Figure 4, 7**), which behaves as a pure
21 PqsR antagonist in an *E. coli* reporter gene assay, displayed a dose-dependent agonistic activity
22 when tested in a *P. aeruginosa* functional assay. This unusual behaviour can be explained by the
23 transformation of compound 1 into compound 2 (**Figure 4, 8**). A product of the *pqs* operon, the
24 enzyme PqsH, which is present in *P. aeruginosa* only, carries out the transformation. The analysis
25 of the molecular structure of the antagonist and of the chemical modification that turns it into an
26 agonist allowed the synthesis of a small library of substituted compounds, among which compound

1 3 (**Figure 4, 9**) showed high potency in the *E. coli* reporter gene assay, but retained its antagonistic
2 activity in *P. aeruginosa* without displaying any agonistic activity [59]. In a recent paper, Ilangovan
3 et al. report the determination of the PqsR crystal structure, which allowed the visualization of the
4 shape of the PQS-binding site. This work in conjunction with the chemical synthesis of PQS
5 analogues resulted in the discovery of potent quinazolinone inhibitors of PqsR. These novel insights
6 into the structure of PqsR provide further opportunities for targeting *P. aeruginosa* QS [62].

7 Farnesol (**Figure 5, 10**) is a sesquiterpene alcohol produced by *Candida albicans* and
8 present in the essential oils of citrus fruits. Beyond its activity as fungal QS molecule [63], it affects
9 PQS production by inhibiting the transcription of the pqs operon. According to the proposed model,
10 farnesol stimulates PqsR interaction with a *pqsA* promoter fragment in the region of the PqsR
11 binding site, causing a non-productive interaction with the *pqsA* promoter that does not lead to
12 transcriptional activation of the *pqsA-E* operon [64]. The result is the impairment of production of
13 pyocyanin, a pseudomonas QS-controlled virulence factor. Farnesol is an interesting molecule,
14 because it is devoid of toxic effects, non mutagenic, and affects biofilm formation by *C. albicans*,
15 *Streptococcus mutans*, and *Staphylococcus aureus* [65]. For an interesting discussion on the
16 interactions between *C. albicans* and *P. aeruginosa*, the reader is referred to [66]. However, farnesol
17 use is hampered by its low solubility in water. In a very recent paper, Bhattacharyya et al. describe a
18 new efficient strategy for the local simultaneous delivery of farnesol and vancomycin in the
19 treatment of multi-resistant *S. aureus* (MRSA) infections [67]. Following the observation that
20 sufficient quantities of vancomycin and farnesol can be incorporated into sol-gel silica applied as
21 thin films on an implant surface, they demonstrated a potent adjuvant effect of farnesol on
22 vancomycin in the inhibition of *in vitro* MRSA experimental infection. Although in this case the
23 mechanism of action proposed for farnesol does not involve the inhibition of QS, the technique is
24 attractive and could be used to prevent or limit the formation of bacterial biofilms on the surfaces of
25 catheter and joint implants.

26

1 **5. Modern approaches based on innovative technologies.**

2 Innovative technologies are being tested in the field of QS control, opening up possibilities that
3 were unthinkable a few years ago.

4 5 **5.1 Chemical methods.**

6 Following the original discovery of the anti-QS activity of natural halogenated furanones
7 (fimbrolides) isolated from *Delisea pulchra*, many analogues have been and are produced by
8 chemical synthesis [68]. Traditional synthetic approaches usually yield small panels of synthetic AI
9 analogues, some of which have proved potent QS modulators. A significant improvement of the QS
10 disrupting activity has been recently obtained by the combination of fimbrolides with NO-donor
11 molecules in hybrid compounds (**Figure 6, 11, 12**) [69]. The combination, which represents the first
12 example of dual-acting molecules with high activity against QS and biofilm formation, is worth of
13 further development. The chemical process typically requires different steps such as individual
14 isolation, purification, and reaction optimization, which for large sets of analogues can rapidly
15 become cumbersome. On the other hand, it usually allows the establishment of correlations between
16 structure and activity. In this regard, Tsuchikama et al. recently reported the synthesis of a panel of
17 analogues of (4S)-4,5-dihydroxy-2,3-pentanedione (DPD), called C4-alkoxy-HPDs, which are more
18 potent than natural AI-2 molecules. These findings highlight how manipulation of the DPD scaffold
19 can provide valuable tools for in-depth studies of the ligand-receptor interactions involved in AI-2-
20 mediated QS, and lay the foundation for future chemical structure-based studies aimed at
21 identifying and developing antagonistic analogues [70]. For a comprehensive review focused on
22 chemical methods including combinatorial synthesis, affinity chromatography, and electrochemical
23 sensing of QS signals, the reader is referred to [71].

24 25 **5.2 Computer-aided investigations.**

1 Among modern approaches, high throughput screening maintains its validity yielding hit molecules
2 often based on new molecular scaffolds [72, 73], but *in silico* investigations are considered more
3 convenient in terms of cost, speed of execution, and potency, being able to screen up to millions of
4 compounds. Examples of results obtained by the use of structure-based virtual screening are the
5 recent identification of inhibitors of *P. aeruginosa* QS from a natural-derivative database [74], and
6 from the ChemBridge library [75]. The *in silico* approach has been used not only for screening
7 purposes, but also for studying QS dynamics [76], and to identify bacterial species that contained
8 both QS and aromatics degrading systems, in order to acquire information for developing novel bio-
9 processing techniques [77].

10 An innovative approach is the production by Schaadt et al. of a multi-level logical model
11 based on computational analysis of a combined regulatory and metabolic network for the three *P.*
12 *aeruginosa* QS systems. The model may be used to analyse how enzyme inhibitors and receptor
13 antagonists affect the formation of AI and virulence factors. In addition, it allows almost
14 quantitative predictions about the effect of inhibitors of AI biosynthesis and antagonists of their
15 corresponding receptor, and the investigation of the effect of reviewed network topologies. In the
16 words of the authors, this approach can serve as a basis for further integrating the effect of random
17 mutations in various parts of the network [78].

18 In order to get a better insight into the regulation of *S. aureus* QS system, Audretsch et al
19 used an innovative approach to model the whole system [79]. Instead of creating a mathematical
20 model, these authors used a Boolean network of nodes centred on the agr locus of *S. aureus*. The *in*
21 *silico* node activation patterns were compared with gene activation patterns obtained from
22 microarray, northern blot, and transcriptome data. The network can easily be manipulated and
23 studied, and has two different steady states: one representing an invasive, toxic phenotype, and the
24 other representing a biofilm producing phenotype. By manipulating the nodes of the simulated
25 network, the model may be used to test theories about mutant strains and to predict the effects of
26 QS inhibitors.

1 Sahner et al. have recently devised a novel approach based on the combination of *in silico* and
2 biophysical methods (surface plasmon resonance, isothermal titration calorimetry, saturation
3 transfer difference, and nuclear magnetic resonance) for the development of *P. aeruginosa* QS
4 inhibitors. They demonstrated that the use of the two methods in combination represents a powerful
5 complement to co-crystallography, and allows the rapid and efficient development of inhibitors. By
6 using this combination technique, these authors identified an irreversible inhibitor that covalently
7 binds to the active site of PqsD, which mediates the formation of the precursor of the *Pseudomonas*
8 quinolone signal (PQS) [80].

9

10 **5.3 Nano-and micro-technologies.**

11 Nanotechnologies can be used to direct bacterial communication, by means of “nanofactory”-loaded
12 biopolymer capsules placed at the midst of bacterial populations [81, 82]. It can be expected that this
13 type of instruments, once developed, could be used to assist or replace the activity of the classic
14 antibiotics, and to extend our knowledge of the QS systems and modulate them, so as to direct the
15 microbiome to operate in a host-friendly manner. The possibility to modulate QS has also been
16 demonstrated by means of titanium dioxide bead coated with AHL [83]. The implications of these
17 experiments include the production of medical devices (catheters, joint and cardiac prosthetic
18 devices) with coated surfaces able to interrupt QS signalling and to avoid biofilm formation.

19 The application of novel technologies derived from quite a different field like 3D printing to
20 study bacterial interactions opens new horizons. By means of a microscopic three-dimensional (3D)
21 printing strategy that enables multiple populations of bacteria to be organized within essentially any
22 3D geometry, including adjacent, nested, and free-floating colonies, it has been possible to obtain
23 the rapid growth of fully enclosed cellular populations that release a number of biologically active
24 molecules, including polypeptides, antibiotics, and QS signals. Using this approach, Connell et al.
25 showed that picoliter-volume aggregates of *S. aureus* can display substantial resistance to β -lactam
26 antibiotics by enclosure within a shell composed of *P. aeruginosa* [84]. The technique takes

1 advantage of thermally set gelatine mixtures as a reagent for micro-3D printing, which provides the
2 ability to print enclosures around any bacterial cell of interest suspended within the hydrogel
3 matrix. In the words of the authors, this manufacturing strategy provides a versatile base for
4 exploring the mechanisms involved in cell communication, which allow bacterial adaptation to the
5 natural environment by means of social behaviour. This technology could perhaps be exploited at
6 its best if coupled with the use of bacteria programmed to sense and destroy highly pathogenic
7 species.

8

9 **5.4 Bacterial bio-engineering**

10 In a recent paper, Gupta et al. describe the engineering of sentinel *E. coli* cells, capable of
11 specifically detecting the QS AI molecule 3OC₁₂HSL, produced by *P. aeruginosa*, and then to
12 synthesize and secrete the chimeric bacteriocin CoPy, specific for PAO1 *P. aeruginosa* [85]. The
13 engineering of *E. coli* consists of three interconnected modules: the detection module, which is
14 activated by the PAO1 QS signal; the destruction module, which produces the toxin; and the
15 secretion module that allows the secretion of CoPy. The effectiveness of the system was assessed by
16 experiments in which the two bacterial species were co-cultured on semi-solid agar plates. The
17 system has two advantages: first, it is possible to change the type of toxin produced; second, in the
18 absence of the pathogen, the system remains in stand-by, but the production starts immediately after
19 the detection of the pathogen.

20 Bacterial QS is also involved in extracellular cell death and in the action of antibiotics,
21 through its interference in a system also called “addiction module”, which can be found in many
22 different Gram-positive and -negative bacteria. The system, which has mainly been studied in *E.*
23 *coli*, consists of a pair of genes whose products are a stable toxin and an unstable antitoxin, which
24 prevents the lethal action of the toxin [86]. In this situation, bacterial survival depends upon the
25 continuous production of the short-lived antitoxin, to which the cell is “addicted”. It has been
26 shown that in *E. coli* the effect of some antibiotics such as rifampicin, chloramphenicol,

1 spectinomycin, and nalidixic acid is due to the inhibition of the antitoxin production, and that this
2 action is dependent upon the presence in the culture of high concentrations of a QS mediator called
3 “extracellular death factor” (EDF) [87, 88]. The *E. coli* EDF is a linear pentapeptide with the amino
4 acid sequence Asn-Asn-Trp-Asn-Asn, which is able to induce programmed cell death also in
5 conditions of cell stress, like amino acid starvation or DNA damage. Recently, it has been shown
6 that one hexapeptide produced by *Bacillus subtilis* and three peptides, one nonapeptide and two
7 hexadecapeptides produced by *P. aeruginosa*, have the same effect of the *E. coli* EDF on *E. coli*
8 cultures [89]. These findings establish the existence of a growing family of EDFs that behave as AI
9 and exert both intra- and inter-specific activity. These molecules may provide a basis for the
10 development of a new class of antibacterials, which could synergize with antibiotics.

11

12 **6. Expert opinion**

13 Despite the huge amount of molecules so far discovered that inhibit the QS mechanisms, the
14 potential of QS inhibition as a future treatment strategy has yet to be fully assessed. In addition,
15 there are obstacles, some obvious, others in the process of being recognized, which hinder the
16 transformation of QS inhibitors into real drugs. The most obvious roadblock, which QS inhibitors
17 share with antibiotics, is the lack of interest of pharmaceutical companies to bear the costs related to
18 the development of hits into drugs that are inevitably bound to have a very limited market. This
19 issue is critical to the future of the treatment of infectious diseases in this so-called post-antibiotic
20 era. In accordance with what has already been proposed for the development of new antibiotics and
21 drugs for neglected diseases, probably the best way to overcome the impasse is the union of skills
22 and funds from private companies, academia and public institutions. In the short term, the
23 knowledge gained so far, especially that concerning plant-derived inhibitors, could perhaps be used
24 in the field of dietary advice and food supplements. Since the pioneering work of Givskov et al. [90]
25 reporting the inhibitory effect of brominated furanones from the Australian macroalga *D. pulchra*
26 on *Serratia liquefaciens* QS-mediated swarming, many plant-derived inhibitors have been

1 identified. For a comprehensive review, the reader is referred to [91]. To improve the characteristics
2 of natural derivatives, a number of synthetic molecules have also been developed, and more than 40
3 have been patented [92, 93, 15, 1]. However, we are still far from having a licensed drug available on
4 the market, if we exclude some antibiotics, such as azithromycin, ceftazidime and ciprofloxacin,
5 which at subinhibitory concentrations block the expression of QS-regulated virulence factors in *P.*
6 *aeruginosa* [94]. In this regard, we must stress the importance of distinguishing between the direct
7 toxic effect of a substance and its inhibiting activity on QS. To this aim, it is essential to verify the
8 effect of QS inhibitors on bacterial viability by using sensitive methods and appropriate controls. In
9 the case of pyrogallol, it has recently been shown that its previously highlighted QS-disrupting
10 activity is a side effect of the peroxide production induced by this compound rather than true QS
11 inhibition [95]. According to Defoirdt et al., many of the results obtained in experiments that make
12 use of QS signal molecule reporter strains may be questioned, due to the possibility that the tested
13 compounds may be toxic to the reporter strains [96]. These authors suggest that toxicity tests more
14 stringent than those implemented so far should be used on molecules proposed as QS inhibitors.

15 Another emerging problem is the possibility that QS inhibitors can select more virulent
16 strains. Resistance to QS inhibitors has been studied by means of mathematical models [97-101], and
17 of *in vitro* experiments [102-104]. Bacterial resistance to brominated furanones is mediated by
18 increased efflux activities. As this kind of resistance overlaps with resistance to antibiotics, the
19 treatments with antibiotics endowed with a strong selective pressure may result in improved
20 resistance to antivirulence compounds (and perhaps vice versa). The finding that some strains
21 isolated from cystic fibrosis patients are resistant to QS inhibitors, corroborates this hypothesis.
22 Additional clinical evidence of the ability of bacteria to evolve resistance to QQ compounds was
23 provided by studying the resistance of *P. aeruginosa* isolated from urine, blood, and catheter tip
24 specimens obtained from Mexican children [104].

25 Other *in vivo* and *in vitro* results reported by Kohler et al. demonstrate that QS inhibition
26 interferes with natural selection towards reduced virulence, and therefore may increase the

1 prevalence of more virulent genotypes [105]. Some concerns about the widespread use of QQ
2 compounds as part of an antibacterial therapy have been raised by the possibility that targeting a
3 specific bacterial group may predispose the patient to infection by other groups. For example, in *S.*
4 *aureus*, but not in *S. epidermidis*, biofilm production is under the agr system control. In this
5 situation, agr inhibition would favour *S. epidermidis*, suggesting that agr antagonists would not be
6 indicated for the control of staphylococcal biofilm infections [106].

7 Interestingly, resistance to QQ compounds may be enhanced by the complex interplay of
8 bacteria with bacteriophages, and it seems that QS constitutes a significant, but so far overlooked,
9 determinant of bacterial susceptibility to phage attack [107]

10 The AHLs often exert toxin-like effects on mammalian cells. Hence, neutralizing antibodies
11 would achieve the double goal of disrupting bacterial QS and protecting the host from toxicity. As
12 discussed above, the disrupting efficacy of antibodies was demonstrated both in *P. aeruginosa* and
13 *S. aureus* QS systems. Based on these results, and taking into account the evolutionary high
14 conservation and extracellular distribution of AI, QS can be considered a good target for active and
15 passive immunotherapy approaches [39]. However, here again some caution is necessary. In a recent
16 paper, Michael-Gayego et al. report that SilCR, a QS peptidic AI produced by Group A (GAS) and
17 G streptococci, effectively decreases bacterial virulence *in vivo*. The effect was also observed in
18 SilCR-vaccinated mice, which developed a more severe disease than non-vaccinated ones [108]. The
19 paradox is that SilCR is the product of a gene belonging to the streptococcal invasion locus, sil,
20 which is a virulence factor involved in GAS spreading into deeper tissues. This is perhaps the first
21 demonstration that antibodies directed against a bacterial component increase the severity of the
22 disease. On the other hand, QS activation can be used to improve the antigenicity and the efficacy
23 of an *E. coli* bacterin preparation to be used for vaccination purposes, as reported by Sturbelle et al.
24 [109]. These examples underline both the potentials of QS exploitation for therapeutic purposes and
25 the need to clarify all aspects of the involved mechanisms.

1 In conclusion, QS inhibition can be considered a promising strategy against infections, especially
2 those associated with biofilm formation, and the discovery of new inhibitory molecules is rapidly
3 progressing. However, to identify a new molecule as a pure QS inhibitor, it is necessary to develop
4 more standardized methods of evaluation, with particular attention to rule out direct toxicity that
5 may mimic a QQ effect. Moreover, concerns about the possible emergence of resistance and
6 adverse effects resulting from the alteration of the microbiome must be properly addressed in-depth.
7 In our view, the current challenge in the field of QS research is not so much to find new inhibitory
8 molecules, but to refine and deepen our knowledge on the QS-based interactions between different
9 bacterial species and between bacteria and the host. Important issues that need further investigation
10 are the impact of QS on the social evolution of bacteria, as well as the impact of bacterial social-
11 driven evolution on the infection of the host. Studies performed in mice [110] and humans [111]
12 demonstrated that cultures containing mixtures consisting of QS cooperators, i.e. autoinducer-
13 producing cells, and cheats, i.e. cells that do not produce autoinducers but benefit of cooperator-
14 produced autoinducers, are less virulent than cultures containing pure cooperators, suggesting that
15 asocial cheats could be exploited to exert a potential therapeutic role [112]. An interesting discussion
16 on bacterial cooperation and its possible relevance in the clinical field can be found at [113].
17 The last, but not least important aspect that must be taken into account is that so far the
18 transformation of laboratory results into viable drugs is almost non-existent [114]. This situation is
19 not expected to improve in the near future, because, as is the case for antibiotics, market forces are
20 insufficient to drive the development of antibacterial drugs based on new scaffolds. The need for
21 long-term, huge investments, and the prospect to see the novel drug indications limited to small
22 number of cases, made many large pharmaceutical companies to quit antibiotic discovery for more
23 profitable therapeutics [115]. The political, medical and public concern about the rising innovation
24 gap in 2009 prompted the U.S. and European Community presidencies to establish a Transatlantic
25 Task Force to address antimicrobial resistance, and the Infectious Diseases Society of America
26 called for a global commitment to develop 10 novel antimicrobials by 2020 [116]. We can envisage

1 that in the near future the synergy between new technical developments and public-private
2 industrial partnerships will bring into being a new harvest of badly needed novel antimicrobials,
3 including antibiotics and antivirulence agents.

4

5 Article highlights:

6

7 The increased frequency of infections caused by multiresistant strains indicates the need for new
8 antibacterial drugs with a low selection pressure. The quenching of bacterial virulence by disrupting
9 QS-dependent intercellular communication is one of the best options to achieve this goal.

10

11 Many natural and synthetic QS inhibitors have been identified by means of modern methods that
12 include high throughput screenings and *in silico* structure-function analysis. About 40 molecules
13 with QS inhibitory activity have been patented.

14

15 The possibility to interrupt QS by means of active or passive immunologic interventions is being
16 evaluated and appears promising.

17

18 The most recent approaches in the field of QS research span from mathematical modelling of the
19 QS systems to the combination of *in silico* and biophysical methods, to the creation of hybrid
20 compounds by fusing fimbrolides with NO-donor molecules, and to the exploitation of the 3D
21 printing technology to study short-distance interspecific bacterial interactions.

22

23 The impact of the social behaviour of bacteria on the microbiome and on the establishment of
24 infections needs further investigation. Some concerns are emerging following the somewhat
25 unexpected discovery that QS inhibitors can exert a selective pressure favouring the establishment

1 of more virulent strains. This aspect should be thoroughly investigated before any QS inhibitor is
2 licensed and put on the market.

3

4 None of the inhibitors identified to date have reached the market yet. This can be attributed in part
5 to the necessity of further basic research and development, and in part to the lack of interest of
6 pharmaceutical companies for the development of drugs with limited market prospects.

7

8

1 Conflict of interest

2 The authors declare no conflict of interest.

3

4 **Bibliography**

5 Papers of special note have been highlighted as either of interest (●) or of considerable interest (●●)
6 to readers.

- 7 1. Jiang T, Minyong L. Quorum sensing inhibitors: a patent review. *Exp Opin Ther Pat* 2013;23:867-
8 94
- 9 2. Fuqua WC, Winans SC, Greenberg EP. Quorum sensing in bacteria: the LuxR-LuxI family of cell
10 density-responsive transcriptional regulators. *J Bacteriol* 1994;176:269-75
- 11 3. Davies D. Understanding biofilm resistance to antibacterial agents. *Nat Rev Drug Discov* 2003;
12 2:114-22
- 13 4. Blackledge MS, Worthington RJ, Melander C. Biologically inspired strategies for combating
14 bacterial biofilms. *Curr Opin Pharmacol* 2013;13:699-706
- 15 5. Tomasz A, Hotchkiss RD. Regulation of the transformability of pneumococcal cultures by
16 macromolecular cell products. *Proc Natl Acad Sci USA* 1964;51:480-7
- 17 6. Nealson KH, Platt T, Hastings JVV. Cellular control of the synthesis and activity of the bacterial
18 luminescent system. *J Bacteriol* 1970;104:313-22
- 19 7. Amara N, Krom BP, Kaufmann GF, et al. Macromolecular inhibition of quorum sensing:
20 enzymes, antibodies, and beyond. *Chem Rev* 2011;111:195-208
- 21 8. Williams P. Quorum sensing: an emerging target for antibacterial chemotherapy. *Exp Opin Ther*
22 *Targets* 2002;6:257-74
- 23 9. Zhang LH, Dong YH. Quorum sensing and signal interference: diverse implications. *Mol*
24 *Microbiol* 2004;53:1563-71
- 25 10. Kalia VC. Quorum sensing inhibitors: an overview. *Biotechnol Adv* 2013;31:224-45

- 1 ●● An updated and very comprehensive overview on natural and synthetic QS inhibitors and their
2 biotechnological applications.
- 3 11. Hentzer M, Givskov M. Pharmacological inhibition of quorum sensing for the treatment of
4 chronic bacterial infections. *J Clin Invest* 2003;112:1300-7
- 5 12. Jacobsen TH, van Gennip M, Phipps RK, et al. Ajoene, a sulfur-rich molecule from garlic, inhibits
6 genes controlled by Quorum Sensing. *Antimicrob Agents Chemother* 2012;56:2314-25
- 7 13. Rasmussen TB, Givskov M. Quorum-sensing inhibitors as anti-pathogenic drugs. *Intern J Med*
8 *Microbiol* 2006;296:149-61
- 9 14. Kaufmann GF, Park J, Janda KD. Bacterial quorum sensing: a new target for anti-infective
10 immunotherapy. *Exp Opin Biol Ther* 2008;8:719-24
- 11 15. Bhardwaj AK, Vinothkumar K, Rajpara N. Bacterial quorum sensing inhibitors: attractive
12 alternatives for control of infectious pathogens showing multiple drug resistance. *Recent Pat*
13 *Antiinfect Drug Discov* 2013;8:68-83
- 14 ●● A clear exposition of the different QS systems and of their inhibitors, with a detailed analysis of
15 the most relevant patents.
- 16 16. Chung J, Goo E, Yu S, et al. Small-molecule inhibitor binding to an N-acyl-homoserine lactone
17 synthase. *Proc Natl Acad Sci USA* 2011;108:12089-94
- 18 17. Chan YY, Chua KL. The *Burkholderia pseudomallei* BpeAB-OprB efflux pump: expression and
19 impact on quorum sensing and virulence. *J Bacteriol* 2005;187:4707-19
- 20 18. Li X, Chu S, Feher VA, et al. Structure-based design, synthesis, and antimicrobial activity of
21 indazole-derived SAH/MTA nucleosidase inhibitors. *J Med Chem.* 2003;46:5663-73
- 22 19. Gutierrez JA, Crowder T, Rinaldo-Matthis A, et al. Transition state analogs of 5'-
23 methylthioadenosine nucleosidase disrupt quorum sensing. *Nat Chem Biol* 2009;5:251-7
- 24 20. Longshaw AI, Adanitsch F, Gutierrez JA, et al. Design and synthesis of potent "sulfur-free"
25 transition state analogue inhibitors of 5'-methylthioadenosine nucleosidase and 5'-
26 methylthioadenosine phosphorylase. *J Med Chem* 2010;53:6730-46

- 1 21. Schramm VL. Methods and compositions for treating bacterial infections by inhibiting quorum
2 sensing. US20110190265; 2011
- 3 22. Calfee MW, Coleman JP, Pesci EC. Interference with *Pseudomonas* quinolone signal synthesis
4 inhibits virulence factor expression by *Pseudomonas aeruginosa*. Proc Natl Acad Sci USA
5 2001; 98:11633-7
- 6 23. Zhou L, Zheng H, Tang Y, et al. Eugenol inhibits quorum sensing at sub-inhibitory
7 concentrations. Biotechnol Lett 2013;35:631-7
- 8 24. Kalia VC, Purohit HJ. Quenching the quorum sensing system: potential antibacterial drug
9 targets. Crit Rev Microbiol 2011;37:121-40
- 10 25. Chen F, Gao Y, Chen X, Yu Z, Li X. Quorum quenching enzymes and their application in
11 degrading signal molecules to block quorum sensing-dependent infection. Int J Mol Sci 2013;14:
12 17477-500
- 13 26. Migiyama Y, Kaneko Y, Yanagihara K, et al. Efficacy of AiiM, an N-acylhomoserine lactonase,
14 against *Pseudomonas aeruginosa* in a mouse model of acute pneumonia. Antimicrob Agents
15 Chemother 2013;57:3653-8
- 16 27. Papaioannou E, Wahjudi M, Nadal-Jimenez P, et al. Quorum-Quenching acylase reduces the
17 virulence of *Pseudomonas aeruginosa* in a *Caenorhabditis elegans* infection model. Antimicrob
18 Agents Chemother 2009;53:4891-7
- 19 28. Wahjudi M, Murugappan S, van Merkerk R, et al. Development of a dry, stable and inhalable
20 acyl-homoserine-lactone-acylase powder formulation for the treatment of pulmonary
21 *Pseudomonas aeruginosa* infections. Europ J Pharmac Sciences 2013;48:637-43
- 22 29. Yang F, Wang LH, Wang J, et al. Quorum quenching enzyme activity is widely conserved in the
23 sera of mammalian species. FEBS Lett 2005;579:3713-7
- 24 30. Camps J, Pujol I, Ballester F, et al. Paraoxonases as potential antibiofilm agents: their relationship
25 with Quorum-Sensing signals in Gram-Negative bacteria. Antimicrob Agents Chemother 2011;
26 55:1325-31

- 1 31. Estin ML, Stoltz DA, Zabner J. Paraoxonase 1, Quorum Sensing, and *P. aeruginosa* infection: a
2 novel model. *Adv Exp Med Biol* 2010;660:183-93
- 3 32. Devarajan A, Bourquard N, Grijalva VR, et al. Role of PON2 in innate immune response in an
4 acute infection. *Mol Genet Metab* 2013;110:362-70
- 5 33. Chowdhary PK, Keshavan N, Nguyen HQ, et al. *Bacillus megaterium* CYP102A1 oxidation of
6 acyl homoserine lactones and acyl homoserines. *Biochemistry* 2007;46:14429-37
- 7 34. Uroz S, Chhabra SR, Camara M, et al. N-Acylhomoserine lactone quorum-sensing molecules are
8 modified and degraded by *Rhodococcus erythropolis* W2 by both amidolytic and novel
9 oxidoreductase activities. *Microbiology* 2005;151:3313-22
- 10 35. Bijtenhoorn P, Mayerhofer H, Muller-Dieckmann J, et al. A novel metagenomic short-chain
11 dehydrogenase/reductase attenuates *Pseudomonas aeruginosa* biofilm formation and virulence on
12 *Caenorhabditis elegans*. *PLoS ONE* 2011;6:e26278
- 13 36. Miyairi S, Tateda K, Fuse ET, et al. Immunization with 3-oxododecanoyl-L-homoserine lactone-
14 protein conjugate protects mice from lethal *Pseudomonas aeruginosa* lung infection. *J Med*
15 *Microbiol* 2006;55:1381-7
- 16 37. Debler EW, Kaufmann GF, Kirchdoerfer RN, et al. Crystal structures of a quorum-quenching
17 antibody. *J Mol Biol* 2007;368:1392-402
- 18 38. Park J, Jagasia R, Kaufmann GF, et al. Infection control by antibody disruption of bacterial
19 quorum sensing signaling. *Chem Biol* 2007;14:1119-27
- 20 39. Kaufmann GF, Park J, Mee JM, et al. The quorum quenching antibody RS2-1G9 protects
21 macrophages from the cytotoxic effects of the *Pseudomonas aeruginosa* quorum sensing
22 signalling molecule *N*-3-oxo-dodecanoyl-homoserine lactone. *Mol Immunol* 2008;45:2710-4
- 23 40. Kirchdoerfer RN, Garner AL, Flack CE, et al. Structural basis for ligand recognition and
24 discrimination of a quorum-quenching antibody. *J Biol Chem* 2011;286:17351-8

- 1 41. Palliyil S, Downhama C, Broadbent I, et al. High sensitivity monoclonal antibodies specific for
2 homoserine lactones protect mice from lethal *Pseudomonas aeruginosa* infections. Appl Environ
3 Microbiol 2014;80:462-9
- 4 42. Hirakawa H, Harwood CS, Pechter KB, et al. Antisense RNA that affects *Rhodopseudomonas*
5 *palustris* quorum-sensing signal receptor expression. Proc Natl Acad Sci USA 2012;109:12141-6
- 6 43. LaSarre B, Federle MJ. Exploiting quorum sensing to confuse bacterial pathogens. Microbiol Mol
7 Biol Rev 2013;77:73-111
- 8 44. Gordon CP, Williams P, Chan WC. Attenuating *Staphylococcus aureus* virulence gene regulation:
9 a medicinal chemistry perspective. J Med Chem 2013;56:1389-404
- 10 45. Hall PR, Elmore BO, Spang CH, et al. Nox2 modification of LDL is essential for optimal
11 apolipoprotein B-mediated control of *agr* Type III *Staphylococcus aureus* Quorum-sensing. PLOS
12 Pathogens 2013;9:e1003166
- 13 46. Mansson M, Nielsen A, Kjørulff L, et al. Inhibition of virulence gene expression in
14 *Staphylococcus aureus* by novel depsipeptides from a marine *Photobacterium*. Mar Drugs
15 2011;9:2537-52
- 16 47. Kiran MD, Adikesavan NV, Cirioni O, et al. Discovery of a quorum-sensing inhibitor of drug-
17 resistant staphylococcal infections by structure-based virtual screening. Mol Pharmacol
18 2008;73:1578-86
- 19 48. Williams P, Cámara M. Quorum sensing and environmental adaptation in *Pseudomonas*
20 *aeruginosa*: a tale of regulatory networks and multifunctional signal molecules. Curr Opin
21 Microbiol 2009;12:182-91
- 22 49. de Kievit T, Seed PC, Nezezon J, et al. RsaL, a novel repressor of virulence gene expression in
23 *Pseudomonas aeruginosa*. J Bacteriol 1999;181:2175-84
- 24 50. Rampioni G, Schuster M, Greenberg EP, et al. RsaL provides quorum sensing homeostasis and
25 functions as a global regulator of gene expression in *Pseudomonas aeruginosa*. Mol Microbiol
26 2007;66:1557-65

- 1 51. Liang H, Duan J, Sibley CD, et al. Identification of mutants with altered phenazine production
2 in *Pseudomonas aeruginosa*. J Med Microbiol 2011;60:22-34
- 3 52. Seet Q, Zhang LH. Anti-activator QslA defines the quorum sensing threshold and response in
4 *Pseudomonas aeruginosa*. Mol Microbiol 2011;80:951-65
- 5 53. Fan H, Dong Y, Wu D, et al. QsIA disrupts LasR dimerization in antiactivation of bacterial
6 quorum sensing. Proc Natl Acad Sci U S A 2013;110:20765-70
- 7 54. Chugani SA, Whiteley M, Lee KM, et al. QscR, a modulator of quorum-sensing signal
8 synthesis and virulence in *Pseudomonas aeruginosa*. Proc Natl Acad Sci U S A 2001;98:2752-7
- 9 55. Siehnel R, Traxler B, An DD, et al. A unique regulator controls the activation threshold of
10 quorum-regulated genes in *Pseudomonas aeruginosa*. Proc Natl Acad Sci U S A
11 2010;107:7916-21
- 12 56. Gupta R, Schuster M. Negative regulation of bacterial quorum sensing tunes public goods
13 cooperation. ISME J 2013;7:2159-68
- 14 57. Weng LX, Yang YX, Zhang YQ, et al. A new synthetic ligand that activates QscR and blocks
15 antibiotic-tolerant biofilm formation in *Pseudomonas aeruginosa*. Appl Microbiol Biotechnol
16 2013;Dec 11. PMID:24327212 [Epub ahead of print]
- 17 58. Lesic B, Lépine F, Déziel E, et al. Inhibitors of pathogen intercellular signals as selective anti-
18 infective compounds. PLoS Pathog 2007;3:1229-39
- 19 59. Lu C, Maurer CK, Kirsch B, et al. Overcoming the Unexpected Functional Inversion of a PqsR
20 Antagonist in *Pseudomonas aeruginosa*: An In Vivo Potent Antivirulence Agent Targeting pqs
21 Quorum Sensing. Angew Chem Int Ed Engl 2014;53:1109-12
- 22 60. Folch B, Déziel E, Doucet N. Systematic mutational analysis of the putative hydrolase PqsE:
23 toward a deeper molecular understanding of virulence acquisition in *Pseudomonas aeruginosa*.
24 PLoS One 2013;8:e73727.

- 1 61. Lu C, Kirsch B, Zimmer C, de Jong JC, et al. Discovery of antagonists of PqsR, a key player in
2 2-alkyl-4-quinolone-dependent quorum sensing in *Pseudomonas aeruginosa*. Chem Biol
3 2012;19:381-90
- 4 62. Ilangovan A, Fletcher M, Rampioni G, et al. Structural basis for native agonist and synthetic
5 inhibitor recognition by the *Pseudomonas aeruginosa* quorum sensing regulator PqsR (MvfR).
6 PLoS Pathog 2013;9:e1003508.
- 7 63. Décanis N, Tazi N, Correia A, et al. Farnesol, a fungal quorum-sensing molecule triggers
8 *Candida albicans* morphological changes by downregulating the expression of different
9 secreted aspartyl proteinase genes. Open Microbiol J 2011;5:119-26.
- 10 64. Cugini C, Calfee MW, Farrow JM 3rd, et al. Farnesol, a common sesquiterpene, inhibits PQS
11 production in *Pseudomonas aeruginosa*. Mol Microbiol 2007;65:896-906
- 12 65. Jabra-Rizk MA, Meiller TF, James CE, et al. Effect of farnesol on *Staphylococcus aureus* biofilm
13 formation and antimicrobial susceptibility. Antimicrob Agents Chemother 2006;50:1463-9
- 14 66. Méar JB, Kipnis E, Faure E, et al. *Candida albicans* and *Pseudomonas aeruginosa* interactions:
15 more than an opportunistic criminal association? Med Mal Infect 2013;43:146-51
- 16 67. Bhattacharyya S, Agrawal A, Knabe C, et al. Sol-gel silica controlled release thin films for the
17 inhibition of methicillin-resistant *Staphylococcus aureus*. Biomaterials 2014;35:509-17
- 18 ● An interesting report on an innovative biomaterial.
- 19 68. Sabbah M, Bernollin M, Doutheau A, et al. A new route towards fimbrolide analogues:
20 importance of the exomethylene motif in LuxR dependent quorum sensing inhibition. Med Chem
21 Commun 2013;4:363-6
- 22 69. Kutty SK, Barraud N, Pham A, et al. Design, synthesis and evaluation of fimbrolide-nitric oxide
23 donor hybrids as antimicrobial agents. J Med Chem 2013;56:9517-29
- 24 ● The paper describes an innovative fusion of two molecules with antibacterial activity.
- 25 70. Tsuchikama K, Zhu J, Lowery CA, et al. C4-alkoxy-HPD: a potent class of synthetic modulators
26 surpassing nature in AI-2 quorum sensing. J Am Chem Soc 2012;134:13562-4

- 1 71. Praneenararat T, Palmer AG, Blackwell HE. Chemical methods to interrogate bacterial quorum
2 sensing pathways. *Org Biomol Chem* 2012;10:8189-99
- 3 72. Desouki SE, Nishiguchi K, Zendo T, et al. High-throughput screening of inhibitors targeting
4 *Agr/Fsr* quorum sensing in *Staphylococcus aureus* and *Enterococcus faecalis*. *Biosci Biotechnol*
5 *Biochem* 2013;77:923-7
- 6 73. Christensen QH, Groveb TL, Booker SJ, et al. A high-throughput screen for quorum-sensing
7 inhibitors that target acyl-homoserine lactone synthases. *Proc Natl Acad Sci* 2013;110: 13815-20
- 8 74. Tan SY-Y, Chua S-L, Chen Y, et al. Identification of five structurally unrelated quorum-sensing
9 inhibitors of *Pseudomonas aeruginosa* from a natural-derivative database. *Antimicrob Agents*
10 *Chemother* 2013;57:5629-41
- 11 75. Skovstrup S, Le Quement ST, Hansen T, et al. Identification of LasR ligands through a virtual
12 screening approach. *Chem Med Chem* 2013;8:157-63
- 13 76. Weber M, Buceta J. Dynamics of the quorum sensing switch: stochastic and non-stationary
14 effects. *BMC Syst Biol* 2013;7:6.
- 15 77. Huang Y, Zeng Y, Yu Z, et al. *In silico* and experimental methods revealed highly diverse
16 bacteria with quorum sensing and aromatics biodegradation systems--a potential broad
17 application on bioremediation. *Bioresour Technol* 2013;148:311-6
- 18 78. Schaadt NS, Steinbach A, Hartmann RW, et al. Rule-based regulatory and metabolic model for
19 Quorum sensing in *P. aeruginosa*. *BMC Systems Biology* 2013;7:81
- 20 79. Audretsch C, Lopez D, Srivastava M, et al. A semi-quantitative model of Quorum-Sensing in
21 *Staphylococcus aureus*, approved by microarray meta-analyses and tested by mutation studies.
22 *Mol BioSyst* 2013;9:2665-80
- 23 80. Sahner JH, Brengel C, Storz MP, et al. Combining *in silico* and biophysical methods for the
24 development of *Pseudomonas aeruginosa* quorum sensing inhibitors: an alternative approach for
25 structure-based drug design. *J Med Chem* 2013;56:8656-64

- 1 81. Hebert CG, Gupta A, Fernandes R, et al. Biological nanofactories target and activate epithelial
2 cell surfaces for modulating bacterial quorum sensing and interspecies signaling. *ACS Nano*
3 2010;4:6923-31
- 4 82. Gupta A, Terrell JL, Fernandes R, et al. Encapsulated fusion protein confers “Sense and
5 Respond” activity to chitosan-alginate capsules to manipulate bacterial quorum sensing.
6 *Biotechnol Bioeng* 2013;110:552-62
- 7 83. Gomes J, Grunau A, Lawrence AK, et al. Bioinspired, releasable quorum sensing modulators.
8 *Chem Commun* 2013;49:155-7
- 9 84. Connell JL, Ritschdorff ET, Whiteley M, et al. 3D printing of microscopic bacterial communities.
10 *Proc Natl Acad Sci* 2013;110:18380-5
- 11 85. Gupta S, Bram EE, Weiss R. Genetically programmable pathogen sense and destroy. *ACS Synth*
12 *Biol* 2013;PMID 23763381
- 13 ● This article demonstrates the feasibility of a futuristic technology that uses bacteria programmed to
14 protect the host.
- 15 86. Guglielmini J, Van Melderen L. Bacterial toxin-antitoxin systems. *Mobile Genetic Elements*
16 2011;1:283-90
- 17 87. Kolodkin-Gal I, Hazan R, Gaathon A, et al. A linear pentapeptide is a quorum-sensing factor
18 required for *mazEF*-mediated cell death in *Escherichia coli*. *Science* 2007;318:652-5
- 19 88. Kolodkin-Gal I, Sat B, Keshet A, et al. The communication factor EDF and the toxin-antitoxin
20 module *mazEF* determine the mode of action of antibiotics. *PLoS Biology* 2008;6:e319
- 21 89. Kumar S, Kolodkin-Gal I, Engelberg-Kulka H. Novel quorum-sensing peptides mediating
22 interspecies bacterial cell death. *mBio* 2013;4:e00314-13
- 23 90. Givskov M, de Nys R, Manefield M, et al. Eukaryotic interference with homoserine lactone-
24 mediated prokaryotic signalling. *J Bacteriol* 1996;178:6618-22
- 25 91. Koh CL, Sam CK, Yin WF, et al. Plant-Derived Natural Products as Sources of Anti-Quorum
26 Sensing Compounds. *Sensors* 2013;13:6217-28

- 1 92. Pan J, Ren D. Quorum sensing inhibitors: a patent overview. *Expert Opin Ther Pat*
2 2009;19:1581-601
- 3 93. Romero M, Acuña L, Otero A. Patents on quorum quenching: interfering with bacterial
4 communication as a strategy to fight infections. *Recent Pat Biotechnol* 2012;6:2-12
- 5 94. Skindersoe ME, Alhede M, Phipps R, et al. Effects of antibiotics on quorum sensing of
6 *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2008;52:3648-63
- 7 95. Defoirdt T, Pande GS, Baruah K, et al. The apparent quorum-sensing inhibitory activity of
8 pyrogallol is a side effect of peroxide production. *Antimicrob Agents Chemother*
9 2013;57:2870-3
- 10 96. Defoirdt T, Brackman G, Coenye T. Quorum sensing inhibitors: how strong is the evidence?
11 *Trends Microbiol* 2013;21:619-24
- 12 ● This is perhaps the first paper highlighting the need for a more stringent evaluation of QS
13 inhibitors.
- 14 97. Dockery JD, Keener JP. A mathematical model for quorum sensing in *Pseudomonas*
15 *aeruginosa*. *Bull Math Biol* 2001;63:95-116
- 16 98. Anguige K, King JR, Ward JP. A multi-phase mathematical model of quorum sensing in a
17 maturing *Pseudomonas aeruginosa* biofilm. *Math Biosci* 2006;203:240-76
- 18 99. Janakiraman V, Englert D, Jayaraman A, et al. Modeling growth and quorum sensing in
19 biofilms grown in microfluidic chambers. *Ann Biomed Eng* 2009;37:1206-16
- 20 100. Fozard JA, Lees M, King JR, et al. Inhibition of quorum sensing in a computational biofilm
21 simulation. *Biosystems* 2012;109:105-14
- 22 101. Beckmann BE, Knoester DB, Connelly BD, et al. Evolution of resistance to quorum
23 quenching in digital organisms. *Artif Life* 2012;18:291-310
- 24 102. Maeda T, García-Contreras R, Pu M, et al. Quorum quenching quandary: resistance to
25 antivirulence compounds. *ISME J* 2012;6:493-501

- 1 103. Kalia VC, Wood TK, Kumar P. Evolution of Resistance to Quorum-Sensing Inhibitors.
2 Microb Ecol 2013; PMID:24194099
- 3 104. García-Contreras R, Martínez-Vázquez M, Velázquez Guadarrama N, et al. Resistance to
4 the quorum-quenching compounds brominated furanone C-30 and 5-fluorouracil in
5 *Pseudomonas aeruginosa* clinical isolates. Pathog Dis 2013;68:8-11
- 6 105. Köhler T, Perron GG, Buckling A, et al. Quorum sensing inhibition selects for virulence and
7 cooperation in *Pseudomonas aeruginosa*. PLoS Pathog. 2010;6:e1000883.
- 8 106. Harraghy N, Kerdudou S, Herrmann M. Quorum-sensing systems in staphylococci as
9 therapeutic targets. Anal Bioanal Chem 2007;387:437-44
- 10 107. Høyland-Kroghsbo NM, Maerkedahl RB, Svenningsen SL. A quorum-sensing-induced
11 bacteriophage defense mechanism. mBio 2013;4:e00362-12
- 12 108. Michael-Gayego A, Dan-Goor M, Jaffe J, et al. Characterization of sil in invasive group A
13 and G streptococci: antibodies against bacterial pheromone peptide SilCR result in severe
14 infection. Infect Immun 2013;81:4121-7
- 15 109. Sturbelle RT, Conceição RC, Da Rosa MC, et al. The use of quorum sensing to improve
16 vaccine immune response. Vaccine 2014;32:90-5
- 17 110. Rumbaugh KP, Diggle SP, Watters CM, et al. Quorum sensing and the social evolution of
18 bacterial virulence. Curr Biol 2009;19:341-45
- 19 111. Köhler T, Buckling A, van Delden C. Cooperation and virulence of clinical *Pseudomonas*
20 *aeruginosa* populations. Proc Natl Acad Sci U S A 2009;106:6339-44
- 21 112. Diggle SP. Microbial communication and virulence: lessons from evolutionary theory.
22 Microbiology 2010;156:3503-12
- 23 113. Harrison F. Bacterial cooperation in the wild and in the clinic: are pathogen social
24 behaviours relevant outside the laboratory? Bioessays 2013;35:108-12
- 25 114. Zhu J, Kaufmann GF. Quo vadis quorum quenching? Curr Opin Pharmacol 2013;13:688-98

1 115. Davies J. How to discover new antibiotics: harvesting the parvome. *Curr Opin Chem Biol*
2 2011;15:5-10

3 116. Gwynn MN, Portnoy A, Rittenhouse SF, et al. Challenges of antibacterial discovery
4 revisited. *Ann NY Acad Sci* 2010;1213:5-19

5

6 Figure legends

7

8 Figure 1

9 Chemical structures of anthranilate (1), methyl anthranilate (2), and PQS (3)

10 Figure 2

11 Chemical structures of N-(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL) (4), and N-
12 butyryl-L-homoserine lactone (C4-HSL) (5)

13 Figure 3

14 Chemical structure of eugenol (6)

15 Figure 4

16 Chemical structures of two PqsR antagonists (7) and (9), and of a PqsR agonist (8) (from Lu et al.,
17 2014)

18 Figure 5

19 Chemical structure of farnesol (10)

20 Figure 6

21 Chemical structures of examples of fimbrolides-NO-donor hybrid compounds (11), (12) (from
22 Kutty et al., 2013)

23

24

25

26






Figure 1





Figure 2






Figure 3




10
11
12
13
14
15
16
17
18
19
20
21
22

7




34
35
36
37
38
39
40
41
42
43
44

8



9


Figure 4



10


Figure 5

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27



R=C₃H₇
R=C₁₁H₂₃

11



12

Figure 6